Recent 8-K filings for FHTX

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Foghorn Q1 net loss $19.9M, cash $183.6M; FHD-909 Phase 1 on track; IND for two degraders expected 2027

  Q1 2026 net loss $19.9M (vs $18.8M loss Q1 2025); collaboration revenue $3.3M (down from $6.0M).

• April 21, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Foghorn presents preclinical data at AACR: FHD-909 combo shows complete regression and immune memory

  FHD-909 (SMARCA2 inhibitor) plus anti-PD-1 achieved complete tumor regression and immune memory in preclinical SMARCA4-mutant models.

• March 11, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 7.01item 9.01

  Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances

  Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.

• February 23, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02item 8.01item 9.01

  Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher

  Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 8.01item 9.01

  Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028

  Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).

• December 4, 2025, 6:59 PM ET leadership materiality 0.50 neutral item 5.02

  Foghorn Therapeutics appoints Jeff Sacher as interim CFO effective Dec 3, 2025

  Jeff Sacher appointed as Treasurer and interim CFO, effective immediately; company continues search for permanent CFO.

• November 7, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Foghorn Therapeutics releases November 2025 investor presentation highlighting precision therapeutics

  Presentation dated November 2025 focuses on the company's unique biology and precision therapeutics platform.

• November 5, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 5.02item 7.01item 9.01

  Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028

  CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.

• October 30, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Foghorn Therapeutics advances three degrader programs; ARID1B degrader selectively degrades ARID1B

  Selective ARID1B degrader shows selective binding and degradation, potentially relevant in up to 5% of solid tumors (endometrial, gastric, bladder, NSCLC).

• September 2, 2025, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Foghorn Therapeutics releases September 2025 investor presentation without new material disclosures

  Presentation reiterates company focus on unique biology, precision therapeutics, and broad impact.

• August 5, 2025, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 7.01item 9.01

  Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track

  Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.

• July 1, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 1.02item 9.01

  Foghorn Therapeutics signs new 9-year lease for 72,846 sq ft HQ in Watertown, MA, terminates Cambridge lease

  New lease at 99 Coolidge Avenue, Watertown for 72,846 sq ft; annual base rent starts at $87/sq ft with partial abatement in years 1-2.

• June 17, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Foghorn Therapeutics stockholders elect four Class II directors, ratify Deloitte as auditor

  Elected Stuart Duty, Neil J. Gallagher, Adrian Gottschalk, and Ian F. Smith as Class II directors for three-year terms.

• May 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs

  Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).

• May 1, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 8.01item 9.01 ◈ executive_change ×2

  Foghorn Therapeutics appoints Neil Gallagher and Stuart Duty to Board of Directors

  Stuart Duty and Neil Gallagher appointed effective May 1, 2025 as Class II directors.

• April 28, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing

  FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.

• March 24, 2025, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Foghorn Therapeutics furnishes investor presentation; no material new information

  Company filed an investor presentation dated March 2025 under Regulation FD.

• March 20, 2025, 7:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  Foghorn Therapeutics reduces ATM program capacity from $200M to $100M

  Amendment No. 1 to Sales Agreement with TD Cowen lowers maximum shares to be sold from $200M to $100M.

• March 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Foghorn Therapeutics reports 2024 net loss $86.6M; cash runway into 2027; key pipeline milestones

  Net loss of $86.6M for FY2024 vs $98.4M in 2023; collaboration revenue $22.6M (down from $34.2M).

• February 3, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Foghorn Therapeutics furnishes February 2025 investor presentation; no specific financial updates in filing excerpt

  Presentation furnished as Exhibit 99.1 for use in investor meetings.

• January 24, 2025, 6:59 PM ET regulatory materiality 0.35 negative item 3.01 ◈ Listing & Compliance Notices

  Foghorn Therapeutics receives Nasdaq non-compliance notice over audit committee composition

  Nasdaq notified Foghorn on Jan 23, 2025 that its audit committee has only two members, violating Listing Rule 5605.

• January 13, 2025, 6:59 PM ET other material materiality 0.65 positive item 2.02item 7.01item 9.01

  Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders

  Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.

• December 30, 2024, 6:59 PM ET leadership materiality 0.30 neutral item 5.02

  Director Adam M. Koppel resigns from Foghorn Therapeutics board

  Adam M. Koppel, M.D., Ph.D., resigned from the Board effective December 29, 2024.

• December 16, 2024, 6:59 PM ET other material materiality 0.65 negative item 7.01item 8.01item 9.01

  Foghorn discontinues FHD-286 in AML; prioritizes pipeline and Lilly collaboration

  FHD-286 + decitabine showed objective responses in Phase 1 but efficacy threshold not met for continued standalone development.

• November 4, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909

  Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.

• October 10, 2024, 7:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers

  First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.

• August 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Foghorn reports Q2 net loss $23M; cash $285M into 2027; FHD-286 AML data Q4; FHD-909 first patient H2 2024

  Net loss $23.0M for Q2 2024 vs $29.5M in Q2 2023; collaboration revenue $6.9M.

• June 26, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Foghorn Therapeutics stockholders re-elect three Class I directors, ratify Deloitte as auditor

  Scott Biller elected with 20,425,665 votes for, 4,930,514 against; 5,014,629 broker non-votes.

• June 3, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Foghorn Therapeutics furnishes June 2024 investor presentation; no specific financial data disclosed

  Presentation dated June 2024 was made available under Regulation FD.

• May 23, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Foghorn Therapeutics furnishes investor presentation; no specific material updates disclosed in exhibit

  Investor presentation title: 'Unique biology, Precision therapeutics, Broad impact' — no additional content provided.

• May 22, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Foghorn Therapeutics raises ~$110M via public offering of common stock and pre-funded warrants

  Sold 12,743,039 shares of common stock at $5.51/share and pre-funded warrants for 7,220,794 shares at $5.5099 each.

• May 20, 2024, 7:59 PM ET other material materiality 0.15 neutral item 7.01item 9.01

  Foghorn Therapeutics files investor presentation; no specific facts available in filing text

  Form 8-K furnished under Item 7.01; presentation dated May 20, 2024.

• May 6, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Foghorn Therapeutics reports Q1 2024 net loss $25.0M; cash $206.7M, runway into H1 2026

  Net loss $25.0M vs $30.5M YoY; collaboration revenue $5.1M, flat vs prior year.

• May 6, 2024, 7:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Foghorn posts investor presentation; no material financial or pipeline updates disclosed

  Company posted a corporate presentation to its website on May 6, 2024, for use in investor meetings.

• April 16, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 8.01item 9.01 ◈ executive_change ×2

  Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024

  Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.

• April 9, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Foghorn reports preclinical AACR data for FHD-909, CBP/EP300 degraders; IND on track Q2 2024

  FHD-909, a first-in-class BRM selective inhibitor, shows ~30-fold selectivity over BRG1 and dose-dependent tumor growth inhibition in BRG1 mutant xenografts.

• March 7, 2024, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024

  Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.

• February 8, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024

  Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event other_material

11 positive 2 negative 25 neutral

source · FHTX on sec.gov